ArticleSouth Asian journal of cancer2025

Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2-ve Early Breast Cancer (EBC).

Purvish M Parikh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.